Arca
Skip to content
Tools
Tools

EUROIMMUN Anti-BP230-CF ELISA (IgG)

Autoantibodies, Skin (Bullous Pemphigoid 180 And Bullous Pemphigoid 230. 510(k) K193115, from Euroimmun Us, Inc. (Mountain Lakes, NJ). Product code OEG, class 2.

As of Nov 22, 2026, K193115 is an FDA 510(k) held by Euroimmun Us, Inc., substantially equivalent on Sep 17, 2020 after 310 days, with no recalls tied to it in FDA's recall database.

  • Review time: 310 days
  • Recalls: 0

Indications for use

As the 510(k) summary states them, read from FDA's summary PDF

The EUROIMMUN Anti-BP230-CF ELISA (IgG) test kit is intended for the qualitative or semi-quantitative determination of immunoglobulin class IgG antibodies against BP230 in human serum and plasma (K3-EDTA, Li+-heparin, Na+-citrate). It is used as an aid in the diagnosis of bullous pemphigoid, in conjunction with other laboratory and clinical findings.

Record

Type
Traditional
Received
Nov 12, 2019
Review panel
Immunology
Regulation
21 CFR 866.5660

One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.